secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001753926-24-001236
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani to start LIBERATE-1 study of GLP-1 implant for obesity in Q4 2024
------------------------------------------------------------------------

- NPM-115 is a 6-month exenatide implant for chronic weight management in obese/overweight patients.
- LIBERATE-1: 24 patients randomized to implant, Bydureon BCise, or semaglutide for 9 weeks.
- Study expected to begin Q4 2024 in Australia; data projected in 2025.
- FDA cleared IND for NPM-119 (type 2 diabetes) in June 2024; company prioritized NPM-115.
- Company plans to use Australian R&D incentives to defray trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001236/0001753926-24-001236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001236/g084331_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer